TABLE 3.
NK, T, TIGIT, CD226, and PD-1 expression from PBMC in MDS and HDs.
| MDS | HD | P | Significance | |
| CD56+NK (%) | 5.967 ± 5.264 | 14.31 ± 6.148 | <0.0001 | **** |
| NK cells (cells/μL) | 180.8 ± 231.5 | 431.9 ± 247.5 | <0.0001 | **** |
| TIGIT+NK (%) | 26.97 ± 15.10 | 10.50 ± 10.10 | 0.0003 | *** |
| CD226+NK (%) | 62.21 ± 16.22 | 86.16 ± 7.447 | <0.0001 | **** |
| CD16+NK (%) | 72.73 ± 20.17 | 92.12 ± 2.835 | <0.0001 | **** |
| CD16–NK (%) | 22.12 ± 19.96 | 4.686 ± 2.355 | <0.0001 | **** |
| CD3+T (%) | 53.02 ± 17.89 | 73.93 ± 11.04 | <0.0001 | **** |
| T cells (cells/μL) | 775.9 ± 378.8 | 1218 ± 623.5 | 0.0154 | * |
| TIGIT+T (%) | 35.42 ± 15.55 | 18.32 ± 23.38 | 0.0006 | *** |
| CD226+T (%) | 53.85 ± 13.70 | 70.96 ± 10.25 | <0.0001 | **** |
| PD-1+T (%) | 31.11 ± 15.62 | 12.73 ± 8.841 | <0.0001 | **** |
| CD4+T (%) | 56.13 ± 14.61 | 38.17 ± 12.09 | 0.0002 | *** |
| TIGIT+CD4+T (%) | 18.18 ± 9.187 | 15.05 ± 15.43 | 0.1002 | NS |
| CD226+CD4+T (%) | 59.47 ± 19.65 | 67.03 ± 14.19 | 0.293 | NS |
| PD-1+CD4+T (%) | 17.53 ± 7.731 | 11.64 ± 13.15 | 0.0127 | * |
| CD3+CD8+T (%) | 35.02 ± 10.79 | 52.48 ± 11.10 | <0.0001 | **** |
| TIGIT+CD8+T (%) | 49.41 ± 19.58 | 13.97 ± 14.76 | <0.0001 | **** |
| CD226+CD8+T (%) | 60.46 ± 12.81 | 73.37 ± 11.79 | 0.0007 | *** |
| PD-1+CD8+T (%) | 47.88 ± 20.22 | 13.19 ± 13.03 | <0.0001 | **** |
MDS, myelodysplastic syndromes; HDs, healthy donors; PBMCs, peripheral blood mononuclear cells; *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001, NS denotes not significant; data are presented as mean ± SD using an unpaired t-test. NK and T cell expression were analyzed between HDs (N = 20) and MDS (N = 26). The expression of TIGIT, CD226, and PD-1 were analyzed between HDs (N = 20) and MDS (N = 30).